PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.
Chinese CRO WuXi PharmaTech is joining forces with the gene therapy experts at ReGenX Bio to hammer out a manufacturing process for the company's potential one-time treatments. Read more >>
Quintiles' banner business came up short in the first quarter, as currency fluctuations bit into revenue and led the world's largest CRO to dial down its full-year guidance. Read more >>
POPULAR COMMENT THREADS
Covance, now a division of LabCorp, has signed a two-year partnership with the Society for Clinical Research Sites, joining a growing list of CROs working to improve communication between sponsors and investigators.
Contract drug developer Avista Pharma Solutions bought the manufacturing, development and animal health services business of rival Scynexis, building up its capacity to take a larger share of an expanding market.
Covance, recently acquired by testing giant LabCorp, has opened a new, expanded clinical research unit in Texas, pairing space for trials alongside a planned patient-service center operated by its parent company.
PRA Health Sciences, looking to find the next generation of clinical researchers, is dialing up its recruitment pitch in hopes of meeting the escalating demand for CRO-run trials around the world.
The recently merged Huntingdon Life Sciences and Harlan Laboratories have convinced their investors to commit up to $125 million in equity financing, lining up the cash they'll need to move forward as a joint entity.
Indian drugmaker Biocon is on the road to taking its in-house CRO public, and the company's founder said she's considering making the company an entirely independent operation.
From Our Sister Sites
Diagnostic assays that usually require a desktop reader that costs several thousand dollars can now be done using a 3-D printed plate that attaches to a smartphone. Even better, the accuracy of the results achieved are comparable to standard laboratory equipment.
On Monday, Allergan agreed to sell off a $40.5 billion piece of its business, inking a pact to exit the generics space with a sale to Teva Pharmaceutical Industries. But CEO Brent Saunders is already thinking about future buys.